Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
RespireRx Pharmaceuticals Inc. develops drug candidates for disorders linked to disrupted neuronal signaling through the RespireRx Group, including EndeavourRx LLC and ResolutionRx Ltd. Company updates center on licensed and patented compound families, including dronabinol assets for obstructive sleep apnea, GABAkines such as KRM-II-81 for neurological and psychiatric indications, and AMPAkines such as CX1739 for spinal cord injury-related bladder function.
Announcements also cover research publications, government-supported development awards, patent-license agreements, subsidiary organization, private financing efforts, and corporate status matters. The company has disclosed that the SEC revoked the Exchange Act registration of its securities under Section 12(j), making securities-registration status part of its durable public-company history.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has entered a material transfer agreement with University College London (UCL) to collaborate on research involving CX1739, its lead AMPAkine, aimed at treating GRIA disorders. These rare genetic diseases affect AMPA receptor functioning, impacting learning and memory. Dr. Ian Coombs is leading efforts to identify specific genetic variants in children with GRIA Disorder to tailor treatments effectively. Positive effects of CX1739 have been noted in animal models, and the study seeks to confirm its therapeutic potential in humans.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) announced the publication of four studies detailing the pharmacological effects of new structural analogs of its lead compound, KRM-II-81. These analogs enhance GABAergic neurotransmission and show promise as anti-seizure agents without sedation. The studies demonstrated that KRM-II-81 effectively addresses epilepsy and pain without developing tolerance. Notably, the analog MP-III-024 proved effective in tremor models related to Parkinson's Disease. The company's focus on advancing KRM-II-81's development aims to facilitate upcoming human studies, potentially leading to breakthrough treatments for conditions lacking adequate therapies.
RespireRx Pharmaceuticals Inc. (OTC: RSPI) announced on March 22, 2023, the appointment of Joseph Siegelbaum as an independent director of its Board. Siegelbaum, previously a partner at Goodwin Procter LLP, brings extensive legal experience and a strong background in nonprofit leadership. Executive Chairman Dr. Lippa expressed confidence that Siegelbaum's expertise will enhance the Board's effectiveness. RespireRx focuses on developing treatments for psychiatric and neurological disorders, including a promising pipeline targeting obstructive sleep apnea and ADHD. The company continues to advance its innovative drug platforms with no approved treatments currently available for these conditions.
On March 1, 2023, ResolutionRx, a wholly-owned subsidiary of RespireRx Pharmaceuticals (OTC: RSPI), announced a services agreement with iNGENu CRO Pty Ltd for clinical research focused on a proprietary dronabinol formulation aimed at treating obstructive sleep apnea and anorexia. The agreement requires an initial deposit of US$50,000, part of a total R&D budget of approximately US$16.5 million. Notable developments include the formation of ResolutionRx, entry into financing arrangements with Radium Capital for R&D tax credits, and plans for further research activities in Australia. The company aims to commence clinical studies pending adequate financing and regulatory approvals.
RespireRx Pharmaceuticals (OTC: RSPI) announced a Letter of Intent and Term Sheet between its wholly-owned subsidiary ResolutionRx Ltd and Radium Capital on January 27, 2023. This partnership aims to establish financing arrangements to access research and development tax credits in Australia. The R&D Tax Incentive could provide ResolutionRx with a 43.5% tax refund to support its efforts in commercializing dronabinol for obstructive sleep apnea treatment. The total budget for this initiative is approximately $16.5 million, with a significant portion expected to qualify for the R&D tax refund.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) announced a significant amendment to its Exclusive License Agreement with the University of Illinois. The changes, effective December 15, 2022, include the elimination of $100,000 annual payments and a reduction of $200,000 in unpaid dues for 2021 and 2022. Future obligations are adjusted, with a $10,000 payment due after the first patient doses in Phase II, among other modifications. The agreement extension includes a 4% royalty on net sales for up to eight years post-patent expiration, increasing minimum payments to $350,000 upon FDA approval. This aims to streamline financial liabilities and enhance drug development focus.